FLINT, Mich., March 6, 2017 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO), will fill prescriptions for
XERMELO™ (telotristat ethyl), the first oral therapy for adults
whose carcinoid syndrome diarrhea is inadequately controlled by
somatostatin analog (SSA) therapy.
XERMELO™ was recently approved with orphan status by the Food
and Drug Administration.
To learn more about Diplomat's rare disease program, visit
diplomat.is/areas-of-excellence/rare-diseases.
"XERMELO™ is a promising new treatment option," said
Paul Urick, Diplomat's president.
"Carcinoid syndrome is life-altering to those who suffer from it,
and now we are able to help them. XERMELO™ will help us deliver the
personal support we promise patients and make a real impact on
their treatment."
Carcinoid syndrome occurs when metastatic carcinoid tumors
overproduce certain chemicals such as serotonin. XERMELO™ targets
tryptophan hydroxylase, an enzyme responsible for excess serotonin
production. XERMELO™ works within tumorous cells to reduce
serotonin production, providing more control for patients over the
disease.
Symptoms of carcinoid syndrome (such as facial flushing,
abdominal pain, heart valve damage, and frequent diarrhea) often
prevent patients from leading active, plannable lives. According to
the American Society of Clinical Oncology, about 12,000 people in
the U.S. are diagnosed with a carcinoid tumor each year.
XERMELO™ is manufactured by Lexicon Pharmaceuticals, Inc. For
full prescribing information, click here.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended Dec. 31,
2015, and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) serves patients and physicians in all 50
states. Headquartered in Flint,
Michigan, the company focuses on medication management
programs for people with complex chronic diseases. Diplomat opened
its doors in 1975 as a neighborhood pharmacy with one essential
tenet: "Take good care of patients and the rest falls into place."
Today, that tradition continues—always focused on improving patient
care and clinical adherence. For more information, visit
diplomat.is.
CONTACT:
Kali Lucas, Public Relations
Specialist
810.768.9580 | press@diplomat.is
Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/diplomat-to-dispense-xermelo-for-patients-with-carcinoid-syndrome-diarrhea-300418252.html
SOURCE Diplomat Pharmacy, Inc.